CN1209362C - 四唑基－苯基乙酰胺的葡糖激酶激活剂 - Google Patents

四唑基－苯基乙酰胺的葡糖激酶激活剂 Download PDF

Info

Publication number
CN1209362C
CN1209362C CNB018163475A CN01816347A CN1209362C CN 1209362 C CN1209362 C CN 1209362C CN B018163475 A CNB018163475 A CN B018163475A CN 01816347 A CN01816347 A CN 01816347A CN 1209362 C CN1209362 C CN 1209362C
Authority
CN
China
Prior art keywords
methyl
phenyl
reaction mixture
mmol
cyclopentyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018163475A
Other languages
English (en)
Chinese (zh)
Other versions
CN1466584A (zh
Inventor
阿奇犬塔罗·西杜瑞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1466584A publication Critical patent/CN1466584A/zh
Application granted granted Critical
Publication of CN1209362C publication Critical patent/CN1209362C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB018163475A 2000-08-15 2001-08-09 四唑基－苯基乙酰胺的葡糖激酶激活剂 Expired - Fee Related CN1209362C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22549400P 2000-08-15 2000-08-15
US60/225,494 2000-08-15

Publications (2)

Publication Number Publication Date
CN1466584A CN1466584A (zh) 2004-01-07
CN1209362C true CN1209362C (zh) 2005-07-06

Family

ID=22845106

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018163475A Expired - Fee Related CN1209362C (zh) 2000-08-15 2001-08-09 四唑基－苯基乙酰胺的葡糖激酶激活剂

Country Status (20)

Country Link
US (3) US6369232B1 (cg-RX-API-DMAC7.html)
EP (1) EP1311504B1 (cg-RX-API-DMAC7.html)
JP (1) JP3961948B2 (cg-RX-API-DMAC7.html)
KR (1) KR100518061B1 (cg-RX-API-DMAC7.html)
CN (1) CN1209362C (cg-RX-API-DMAC7.html)
AR (1) AR031718A1 (cg-RX-API-DMAC7.html)
AT (1) ATE297921T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001283998B2 (cg-RX-API-DMAC7.html)
BR (1) BR0113312A (cg-RX-API-DMAC7.html)
CA (1) CA2419416C (cg-RX-API-DMAC7.html)
DE (1) DE60111540T2 (cg-RX-API-DMAC7.html)
DK (1) DK1311504T3 (cg-RX-API-DMAC7.html)
ES (1) ES2243541T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001275A (cg-RX-API-DMAC7.html)
PA (1) PA8525201A1 (cg-RX-API-DMAC7.html)
PE (1) PE20020386A1 (cg-RX-API-DMAC7.html)
PT (1) PT1311504E (cg-RX-API-DMAC7.html)
UY (1) UY26885A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002014312A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200300904B (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
CN101805358A (zh) * 2002-10-03 2010-08-18 诺瓦提斯公司 作为葡糖激酶激活剂、可用于治疗ⅱ型糖尿病的取代的(噻唑-2-基)酰胺或磺酰胺
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
AU2003294376A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7262196B2 (en) * 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
WO2005095418A1 (en) 2004-04-02 2005-10-13 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
CA2561157A1 (en) 2004-04-02 2005-10-13 Novartis Ag Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
EP1902052B1 (en) 2005-07-09 2012-11-28 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
BRPI0613451A2 (pt) 2005-07-11 2011-01-11 Mitsubishi Tanabe Pharma Corp ativador de glicocinase, derivado de oxima, método para a preparação do referido derivado de oxima e uso
RU2008112184A (ru) 2005-08-31 2009-10-10 Астеллас Фарма Инк. (Jp) Производное тиазола
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CN101272784A (zh) 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
JP2009514835A (ja) * 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
BRPI0619980A2 (pt) * 2005-12-15 2014-10-14 Nihon Nohyaku Co Ltd Derivados de ftalamida e de anilina, inseticida agrícola ou hortícula, e, método de uso do mesmo
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2049518B1 (en) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
US7910747B2 (en) * 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
EP2105435A4 (en) * 2007-01-10 2011-06-15 Mitsubishi Tanabe Pharma Corp Hydrazone derivative
EP2116533B1 (en) 2007-03-07 2013-07-10 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
AU2008310519B2 (en) * 2007-10-08 2013-05-02 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
CL2009000004A1 (es) * 2008-01-15 2010-02-19 Lilly Co Eli Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
KR20100113518A (ko) * 2008-01-18 2010-10-21 아스텔라스세이야쿠 가부시키가이샤 페닐아세트아미드 유도체
NZ588462A (en) 2008-04-28 2012-07-27 Kyorin Seiyaku Kk Cyclopentylacrylic acid amide derivative
ES2624780T3 (es) 2010-03-31 2017-07-17 The Scripps Research Institute Reprogramación de células

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776917A (en) * 1972-06-05 1973-12-04 Schering Corp 2-amino-6-phenalkyl-aminopyridines and derivatives thereof
GB8909574D0 (en) 1989-04-26 1989-06-14 Ici Plc Chemical process
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
US5461049A (en) * 1994-05-27 1995-10-24 Warner-Lambert Company Amide tetrazole ACAT inhibitors
TR199902442T2 (xx) * 1997-01-28 2000-07-21 Merck & Co.,Inc. �eker ve �i�manl�k tedavisinde �3 agonistleri olarak tiazol benzens�lfonamidler.
TR200102805T2 (tr) * 1999-03-29 2002-04-22 F.Hoffmann-La Roche Ag Glikokinaz aktivatörleri

Also Published As

Publication number Publication date
AU2001283998B2 (en) 2005-10-20
UY26885A1 (es) 2002-02-28
ZA200300904B (en) 2004-04-30
CA2419416A1 (en) 2002-02-21
DE60111540T2 (de) 2006-03-16
KR100518061B1 (ko) 2005-09-28
JP2004506632A (ja) 2004-03-04
AU8399801A (en) 2002-02-25
EP1311504A1 (en) 2003-05-21
CN1466584A (zh) 2004-01-07
KR20030022408A (ko) 2003-03-15
US6441180B1 (en) 2002-08-27
US6369232B1 (en) 2002-04-09
EP1311504B1 (en) 2005-06-15
CA2419416C (en) 2009-10-13
PE20020386A1 (es) 2002-05-13
US20020035267A1 (en) 2002-03-21
PA8525201A1 (es) 2002-07-30
AR031718A1 (es) 2003-10-01
ES2243541T3 (es) 2005-12-01
DE60111540D1 (de) 2005-07-21
JP3961948B2 (ja) 2007-08-22
US20020065275A1 (en) 2002-05-30
DK1311504T3 (da) 2005-10-17
BR0113312A (pt) 2003-07-01
WO2002014312A1 (en) 2002-02-21
ATE297921T1 (de) 2005-07-15
PT1311504E (pt) 2005-10-31
MXPA03001275A (es) 2003-06-30
US20020035266A1 (en) 2002-03-21
US6388088B1 (en) 2002-05-14

Similar Documents

Publication Publication Date Title
CN1209362C (zh) 四唑基－苯基乙酰胺的葡糖激酶激活剂
CN1185219C (zh) 反式烯属葡糖激酶活化剂
CN1226294C (zh) 稠合的杂芳族葡萄糖激酶活化剂
CN1184214C (zh) α－酰基和α－杂原子取代的苯乙酰胺葡糖激酶活化剂
CN1247574C (zh) 异吲哚啉－1－酮葡糖激酶激活剂
CN1151140C (zh) 葡糖激酶活化剂
CN1245394C (zh) 作为葡糖激酶激活剂的取代的苯乙酰胺及其用途
CN1185220C (zh) 对－胺基取代的苯基酰胺葡糖激酶激活剂
CN1066436C (zh) 新的环己烷和环己烯类衍生物
CN1649859A (zh) 取代的苯基乙酰胺类及其作为葡糖激酶激活剂的应用
CN1688574A (zh) 作为葡糖激酶(gk)激活剂的吲哚－3－甲酰胺
CN1050018A (zh) 苯甲酰基胍、它们的制备方法、它们作为药剂的应用以及含有它们的药剂
CN1213307A (zh) 新的取代的咪唑化合物
CN1060652A (zh) 草酰胺类
CN1897936A (zh) 环状胍、含有这种化合物的组合物及其使用方法
CN1845909A (zh) 作为嗜中性白细胞弹性蛋白酶抑制剂的喹喔啉衍生物及它们的用途
CN1374082A (zh) 糖原磺酸化酶抑制剂的用途
AU2001283998A1 (en) Tetrazolyl-phenyl acetamide glucokinase activators
CN1056684A (zh) 异唑-4-羧酰胺及羟基亚烷基氰乙酰胺，含有这些化合物的药物及它们的应用
CN1305454A (zh) 作为cgmp－磷酸二酯酶抑制剂的邻氨基苯甲酸衍生物
CN1171785A (zh) 嘧啶衍生物
CN1290842C (zh) 用作高选择性环加氧酶－2抑制剂的二芳基1,2,4－三唑衍生物
CN1090020C (zh) 4,4－(二取代)环己－1－醇单体及相关的化合物
CN1292744C (zh) 抑制整联蛋白与其受体结合的羧酸衍生物
CN1993336A (zh) 取代的n－酰基－2－氨基噻唑

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050706

Termination date: 20120809